-
公开(公告)号：US20210324094A1
公开(公告)日：2021-10-21
申请号：US17285367
申请日：2019-10-18
Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
Inventor： Ki Joon CHO , Mijung LEE , Eun Jung SONG , Ki Su KIM , Kwan Yub KANG , Eui Cheol CHO
Abstract: An asymmetric fusion protein in which a fragment of an antibody binding to an insulin receptor, an iduronate-2-sulfatase (IDS) enzyme, and an Fc region are fused, and a use thereof are disclosed. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation.
-
公开(公告)号：US20200317779A1
公开(公告)日：2020-10-08
申请号：US16754431
申请日：2018-10-22
Inventor： Ki Su KIM , Jun Hong JEONG , Ae Rin YOON , Eun Jung SONG , Hye Ji CHOI , Ok Jae LIM , Yun Jung LEE , Hyung Kwon LIM , Jong Wha WON
IPC: C07K16/28
Abstract: The present invention relates to an anti-CD3 antibody and a pharmaceutical composition for cancer treatment comprising same. The antibody according to the present invention has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.
-
3.发明申请公开(公告)号：US20200262928A1
公开(公告)日：2020-08-20
申请号：US16651908
申请日：2018-10-22
Inventor： Ki Su KIM , Jung Hong JEONG , Dong Sik KIM , Yang Mi LIM , Yong Yea PARK , Hyung Kwon LIM , Jong Wha WON
Abstract: The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.
-
-
Search Results
3
records
(took 0.01 seconds)
